AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Radiation-Induced Parotid Gland Hypofunction

Conditions

Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer

Trial Timeline

Jun 30, 2019 → Mar 28, 2023

NCT ID

NCT04043104

About AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands) is a phase 1 stage product being developed by MeiraGTx for Radiation-Induced Parotid Gland Hypofunction. The current trial status is completed. This product is registered under clinical trial identifier NCT04043104. Target conditions include Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Radiation-Induced Parotid Gland Hypofunction were approved

Approved (0) Terminated (1) Active (0)

❌oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxideViatrisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04043104	Phase 1	Completed	Jun 30, 2019	Mar 28, 2023	Radiation-Induced Parotid Gland Hypofunction

Competing Products

2 competing products in Radiation-Induced Parotid Gland Hypofunction

See all competitors

Product	Company	Stage	Hype Score
Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）	Sun Pharmaceutical	Phase 2/3	45
oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxide	Viatris	Phase 3	29